Compare Abeona Therapeutics Inc (ABEO) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Charles Schwab Corporation Common Stock — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Charles Schwab Corporation Common Stock trades at $102.35 (market cap $177.27B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 474.8× Abeona Therapeutics Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.26% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SCHW | |
|---|---|---|
Market Cap | $373.32M | $177.27B |
Sector | Health | Financials |
52-Week High | $7.23 | $107.21 |
52-Week Low | $4.17 | $85.35 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 1.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Charles Schwab (SCHW) trades at $101.93, up 5.08% with strong technical momentum and bullish moving averages. The stock shows robust fundamentals with a 37.99% net income margin and consistent earnings beats, including Q1 2026 EPS of $1.43 exceeding expectations. Recent news highlights retail trading growth and a new prediction market venture with Cboe, supporting positive sentiment.
Outlook remains favorable with a $120.38 analyst price target implying 18% upside, though overbought RSI signals near-term caution. Key risks include interest rate sensitivity and competitive pressures. Wall Street consensus is bullish with 58% buy ratings, reflecting confidence in Schwab's revenue diversification and asset growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
